AbbVie Inc. $ABBV Stock: Evergreen Capital Management LLC Grows Stake

Evergreen Capital Management LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 11.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,672 shares of the company's stock after acquiring an additional 5,756 shares during the period. Evergreen Capital Management LLC's holdings in AbbVie were worth $15,086,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Ranch Capital Advisors Inc. lifted its stake in shares of AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock valued at $3,238,000 after acquiring an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock valued at $112,516,000 after acquiring an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in AbbVie during the 2nd quarter worth $23,557,000. Wedge Capital Management L L P NC increased its holdings in AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock worth $33,865,000 after purchasing an additional 9,380 shares in the last quarter. Finally, State Street Corp increased its holdings in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ABBV. Guggenheim reiterated a "buy" rating and set a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. Royal Bank Of Canada reissued an "outperform" rating and set a $280.00 target price on shares of AbbVie in a research note on Tuesday, October 13th. Bank of America restated a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Argus increased their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, Wolfe Research raised AbbVie from a "peer perform" rating to an "outperform" rating and upped their price target for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $279.86.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $285.66 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40. The company's 50-day moving average is $266.33 and its 200 day moving average is $241.77. The company has a market capitalization of $504.70 billion, a P/E ratio of 80.69, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.